Cyr61 is up‐regulated in prostate cancer and associated with the p53 gene status
Abstract
Cysteine‐rich 61 (Cyr61) is a member of the CCN protein family that has been implicated in diverse biological processes such as cell adhesion, proliferation, angiogenesis, and tumorigenesis. Altered expression of Cyr61 is found to be associated with human cancers. Here we show that Cyr61 was up‐regulated in prostate cancer cell lines and tumor tissues. A significant correlation of Cyr61 expression was found between benign prostatic hyperplasia and prostate cancer ( P = 0.002). However, there was no significant correlation between levels of PSA and Cyr61 expression ( P = 0.2). Cyr61 may represent an independent prostate cancer biomarker and potentially a useful therapeutic target for prostate cancer treatment. In addition, our analysis based on published data and data present in this report indicted that levels of Cyr61 expression associated with the status of the tumor suppressor gene p53 in 32 cancer cell lines analyzed, high levels of Cyr61 expression were found in cell lines with mutant or null p53 gene, whereas lower expression levels of Cyr61 in the cell lines with wild‐type p53 . We further show that over‐expression of dominant negative p53 or down‐expression of endogenous wild‐type p53 resulted in up‐regulation of Cyr61 expression, suggesting a functional link between Cyr61 and p53 in cancers. J. Cell. Biochem. 106: 738–744, 2009. © 2009 Wiley‐Liss, Inc.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High levels of CCN1 expression are found in prostate cancer cell lines with mutant or null p53, while lower levels are found in cells expressing wild-type p53.
“Interestingly, high levels of CCN1 expression are found in prostate cancer cell lines with a mutant or null p53 gene, but lower levels are found in cells expressing wild-type p53 [156].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [156]
Cites
1 retracted
Tong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86 · see citing works
RetractedOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · cited 2× · see citing works
“PLASMIDS, siRNA, AND TRANSFECTIONS cDNA encoded the wild-type p53 or dominant-negative p53 [Serrano et al., 1997] was cloned into pcDNA3.”
MethodHan, D. K. M., Eng, J. K., Zhou, H., & Aebersold, R. H. (2001) · Nature Biotechnology · doi:10.1038/nbt1001-946 · Cited by 868 · see citing works
Self-citationCCN proteins: multifunctional signalling regulators
Perbal, B. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15172-0 · Cited by 704 · see citing works
All in the CCN family: essential matricellular signaling modulators emerge from the bunker
Leask, A., & Abraham, D. (2006) · Journal of Cell Science · doi:10.1242/jcs.03270 · Cited by 653 · see citing works
The CCN Family of Angiogenic Regulators: The Integrin Connection
Lau, L. F., & Lam, S. C.-T. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4456 · Cited by 645 · see citing works
Functions and mechanisms of action of CCN matricellular proteins
Chen, C.-C., & Lau, L. F. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.025 · Cited by 549 · see citing works
Pathological and molecular aspects of prostate cancer
Marzo, A. M. D., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12779-1 · Cited by 471 · see citing works
Bello, D. (1997) · Carcinogenesis · doi:10.1093/carcin/18.6.1215 · Cited by 433 · see citing works
Cyr61 promotes breast tumorigenesis and cancer progression
Tsai, M.-S., Bogart, D. F., Castañeda, J. M., Li, P., & Lupu, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205682 · Cited by 189 · see citing works
Xie, D., Yin, D., Wang, H., Liu, G., Elashoff, R. M., Black, K. L., & Koeffler, H. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0659-03 · Cited by 179 · see citing works
Xie, D., Yin, D., Tong, X., O’Kelly, J., Mori, A., Miller, C. W., Black, K. L., Gui, D., Said, J. W., & Koeffler, H. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0666 · Cited by 172 · see citing works
Connective Tissue Growth Factor and Its Role in Lung Adenocarcinoma Invasion and Metastasis
Chang, C., Shih, J., Jeng, Y., Su, J.-L., Lin, B.-Z., Chen, S., Chau, Y., Yang, P., & Kuo, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh059 · Cited by 172 · see citing works
Functional properties and intracellular signaling of CCN1/Cyr61
Chen, Y., & Du, X. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21194 · Cited by 167 · see citing works
Xie, D., Miller, C. W., O'Kelly, J., Nakachi, K., Sakashita, A., Said, J. W., Gornbein, J., & Koeffler, H. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009755200 · Cited by 146 · see citing works
The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Lin, M. Z., Teitell, M. A., & Schiller, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.129.11.1 · Cited by 136 · see citing works
Expression of Cyr61, CTGF, and WISP-1 Correlates with Clinical Features of Lung Cancer
Chen, P.-P., Li, W., Wang, Y., Zhao, S., Li, D.-Y., Feng, L.-Y., Shi, X., Koeffler, H. P., Tong, X.-J., & Xie, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000534 · Cited by 132 · see citing works
The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts
Todorovicç, V., Chen, C.-C., Hay, N., & Lau, L. F. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504015 · Cited by 132 · see citing works
Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line
Bae-Jump, V. L., Jackson‐Cook, C. K., Maygarden, S. J., Plymate, S. R., Chen, J., & Ware, J. L. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980301)34:4 · Cited by 117 · see citing works
Proteomic identification of differentially‐expressed genes in human gastric carcinomas
Nishigaki, R., Osaki, M., Hiratsuka, M., Toda, T., Murakami, K., Jeang, K., Ito, H., Inoue, T., & Oshimura, M. (2005) · PROTEOMICS · doi:10.1002/pmic.200401307 · Cited by 116 · see citing works
Stephan, C., Jung, K., Lein, M., Sinha, P. K., Schnorr, D., & Loening, S. A. (2000) · PubMed · Cited by 106 · see citing works
Sampath, D., Winneker, R. C., & Zhang, Z. (2001) · Endocrinology · doi:10.1210/endo.142.6.8186 · Cited by 97 · see citing works
Inhibition of centrosome protein assembly leads to p53-dependent exit from the cell cycle
Sršeň, V., Gnadt, N., Dammermann, A., & Merdes, A. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200606051 · Cited by 97 · see citing works
Lin, M.-T., Zuon, C.-Y., Chang, C.-C., Chen, S., Chen, C., Lin, B., Wang, M., Jeng, Y., Chang, K., Lee, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2639 · Cited by 90 · see citing works
Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer
Pilarsky, C. P., Schmidt, U., Eißrich, C., Stade, J., Froschermaier, S. E., Haase, M., Faller, G., Kirchner, T., & Wirth, M. P. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980701)36:2 · Cited by 84 · see citing works
Holloway, S. E., Beck, A. W., Girard, L., Jaber, R., Barnett, C. C., Brekken, R. A., & Fleming, J. B. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.10.005 · Cited by 72 · see citing works
The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p
Jay, P., Bergé-Lefranc, J. L., Marsollier, C., Méjean, C., Taviaux, S., & Berta, P. (1997) · Oncogene · doi:10.1038/sj.onc.1200986 · Cited by 67 · see citing works
Bloodborne biomolecular markers in prostate cancer development and progression
Bok, R., & Small, E. J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc951 · Cited by 61 · see citing works
Feng, P., Wang, B., & Ren, E. C. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.06.020 · Cited by 51 · see citing works
Report on the second international workshop on the CCN family of genes
Perbal, B. (2003) · Molecular Pathology · doi:10.1136/mp.56.2.80 · Cited by 50 · see citing works
The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker?
Heidenberg, H. B., Bauer, J. J., McLeod, D. G., Moul, J. W., & Srivastava, S. K. (1996) · Urology · doi:10.1016/s0090-4295(96)00365-2 · Cited by 50 · see citing works
Sakamoto, S., Yokoyama, M., Zhang, X., Kulkarni, P., Nagao, K., Hatanaka, T., Getzenberg, R. H., & Kakehi, Y. (2004) · Endocrinology · doi:10.1210/en.2003-1350 · Cited by 50 · see citing works
Self-citationDowning, S. R., Jackson, P., & Russell, P. J. (2001) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(00)00119-8 · Cited by 36 · see citing works
Sakamoto, S., Yokoyama, M., Aoki, M., Suzuki, K., Kakehi, Y., & Saito, Y. (2004) · The Prostate · doi:10.1002/pros.20098 · Cited by 33 · see citing works
Expression of connective tissue growth factor in pancreatic cancer cell lines
Kwon, S. W., Munroe, X., Crawley, S., Lee, H. J., Spong, S. M., Bradham, D. M., Gum, J. R., Sleisenger, M. H., & Kim, Y. S. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.4.693 · Cited by 31 · see citing works
Sakamoto, S., Yokoyama, M., Kulkarni, P., Tsuruha, J.-I., Masamoto, S., Getzenberg, R. H., & Kakehi, Y. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103259159 · Cited by 14 · see citing works
Up-Regulation of cyr61 in Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats
Unoki‐Kubota, H., Furukawa, K., Yonekura, H., Ueda, Y., Katsuda, S., Mori, M., Nakagawara, K.-I., Mabuchi, H., & Yamamoto, H. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000079329.07787.7f · Cited by 10 · see citing works
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
CCN1/CYR61: the very model of a modern matricellular protein
Lau, L. F. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0778-3 · Cited by 338 · see citing works
Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review)
Li, J., Ye, L., Owen, S., Weeks, H. P., Zhang, Z., & Jiang, W. G. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2390 · Cited by 120 · see citing works
The Matrix Revolution: Matricellular Proteins and Restructuring of the Cancer Microenvironment
Gerarduzzi, C., Hartmann, U., Leask, A., & Drobetsky, E. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-18-2098 · Cited by 96 · see citing works
The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis.
Zuo, G., Kohls, C. D., He, B., Chen, L., Zhang, W., Shi, Q., Zhang, B. Q., Kang, Q., Luo, J., Luo, X., et al. (2010) · PubMed · doi:10.14670/hh-25.795 · Cited by 87 · see citing works
Nuclear retention of mRNAs – quality control, gene regulation and human disease
Wegener, M., & Müller-McNicoll, M. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.11.001 · Cited by 86 · see citing works
Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy
Juan, W. C., & Hong, W. (2016) · Genes · doi:10.3390/genes7090055 · Cited by 84 · see citing works
WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to Bone
Ono, M., Inkson, C. A., Sonn, R., Kilts, T. M., de Castro, L. F., Maeda, A., Fisher, L. W., Robey, P. G., Berendsen, A. D., Li, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071709 · Cited by 66 · see citing works
Role of the CCN protein family in cancer
Kim, H., Son, S., & Shin, I. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.10.192 · Cited by 51 · see citing works
Expression of CTGF and Cyr61 in colorectal cancer
Ladwa, R., Pringle, H., Kumar, R., & West, K. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.082768 · Cited by 50 · see citing works
Jiang, Y. Y., Yang, Q., Xu, Q., Lu, S., Hu, L., Xu, M., & Liu, Y. (2019) · Analytical Biochemistry · doi:10.1016/j.ab.2019.04.020 · Cited by 42 · see citing works
Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic
Sarkar, S., Quinn, B. A., Shen, X., Dash, R., Das, S. K., Emdad, L., Klibanov, A. L., Wang, X., Pellecchia, M., Sarkar, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3544 · Cited by 35 · see citing works
Thakur, R. K., & Mishra, D. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.002 · Cited by 33 · see citing works
Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer
Cai, Z., Lv, H., Cao, W., Zhou, C., Liu, Q., Li, H., & Zhou, F. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7487 · Cited by 25 · see citing works
Self-citationBannur, Z., Teh, L. K., Hennesy, T., Rosli, W. R. W., Mohamad, N., Nasir, A., Ankathil, R., Zakaria, Z. A., Baba, A., & Salleh, M. Z. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.02.013 · Cited by 24 · see citing works
TET1-mediated different transcriptional regulation in prostate cancer.
Feng, J., Wang, Q., Li, G., Zeng, X., Kuang, S., Li, X., & Yue, Y. (2015) · Europe PMC (PubMed Central) · Cited by 22 · see citing works
Zhao, D., Xia, L., Geng, W., Xu, D., Zhong, C., Zhang, J., & Xia, Q. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15674 · Cited by 20 · see citing works
Spencer, C., Montalvo, J., McLaughlin, S. R., & Bryan, B. A. (2011) · PubMed · Cited by 19 · see citing works
Samaržija, I. (2023) · Biomedicines · doi:10.3390/biomedicines12010079 · Cited by 15 · see citing works
CYR61 as a Potential Biomarker and Target in Cancer Prognosis and Therapies
Schenker, A. J., & Ortiz-Hernández, G. L. (2025) · Cells · doi:10.3390/cells14110761 · Cited by 13 · see citing works
Li, J., Gao, X., Ji, K., Sanders, A. J., Zhang, Z., Jiang, W. G., Ji, J., & Ye, L. (2016) · Oncology Reports · doi:10.3892/or.2016.5074 · Cited by 8 · see citing works
Amid, A., Chik, W. D. W., Jamal, P., & Hashim, Y. Z. H.-Y. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.12.6319 · Cited by 6 · see citing works
Role for CCN1 in lysophosphatidic acid response in PC‐3 human prostate cancer cells
Balijepalli, P., Knode, B. K., Nahulu, S. A., Abrahamson, E. L., Nivison, M. P., & Meier, K. E. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12019 · Cited by 4 · see citing works
Lee, Y., Kim, K. D., Park, S. Q., Kim, D. S., Choi, Y. S., Nam, H. S., Lee, S.-H., & Cho, M. K. (2024) · Annals of Dermatology · doi:10.5021/ad.24.008 · Cited by 4 · see citing works
Analysis of novel targets in the pathobiology of prostate cancer
D'Antonio, K. B. (2009) · Cited by 2 · see citing works
Lee, Y., Lee, D. M., Jeong, D., Shim, J., Lee, C.-H., Choi, Y., Nam, H.-S., Cho, M. K., & Lee, S.-H. (2013) · Animal Cells and Systems · doi:10.1080/19768354.2013.830647
Role of p53 and its isoforms in the expression of FGF-2 and tumoral neovascularization
Bernard, H. (2010) · Discovery Research Portal (University of Dundee)
- Authors
- Lv, H., Fan, E., Sun, S., Ma, X., Zhang, X., Han, D. M. K., & Cong, Y.
- Affiliations
- Beijing Normal University (CN)
- UConn Health (US)
- Corresponding author
- Cong, Yu‐Sheng
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2009-01-29
- Volume
- 106
- Issue
- 4
- Pages
- 738-744
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2154984951
- Cited by
- 26
- References
- 38
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cellular Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Rheumatology › Bone and Dental Protein Studies
- Keywords
- CYR61, CCN proteins, prostate cancer, p53, benign prostatic hyperplasia, tumor markers, therapeutic target, dominant-negative p53, TP53 mutation, gene expression correlation, prostate-specific antigen
- MeSH terms
- Humans, Male, Neoplasm Proteins, Prostatic Neoplasms, Up-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cell Line, Tumor, Cysteine-Rich Protein 61
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
